Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells.
Journal
RSC medicinal chemistry
ISSN: 2632-8682
Titre abrégé: RSC Med Chem
Pays: England
ID NLM: 101759460
Informations de publication
Date de publication:
17 Nov 2021
17 Nov 2021
Historique:
received:
26
02
2021
accepted:
05
08
2021
entrez:
26
11
2021
pubmed:
27
11
2021
medline:
27
11
2021
Statut:
epublish
Résumé
Paediatric glioblastomas are rapidly growing, devastating brain neoplasms with an invasive phenotype. Radiotherapy and chemotherapy, which are the current therapeutic adjuvant to surgical resection, are still associated with various toxicity profiles and only marginally improve the course of the disease and life expectancy. A considerable body of evidence supports the antitumour and apoptotic effects of certain cannabinoids, such as WIN55,212-2, against a wide spectrum of cancer cells, including gliomas. In fact, we previously highlighted the potent cytotoxic activity of the cannabinoid ligand
Identifiants
pubmed: 34825187
doi: 10.1039/d1md00065a
pii: d1md00065a
pmc: PMC8597418
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1910-1925Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
J Med Chem. 2006 Jan 12;49(1):70-9
pubmed: 16392793
Oncotarget. 2014 Aug 15;5(15):5852-72
pubmed: 25115386
J Med Chem. 2016 Feb 11;59(3):1052-67
pubmed: 26756097
FEBS Lett. 2006 Mar 20;580(7):1733-9
pubmed: 16500647
Neurosurgery. 2008 Feb;62(2):493-503; discussion 503-4
pubmed: 18382329
J Cell Biochem. 2018 Sep;119(9):7747-7756
pubmed: 29905031
J Mol Signal. 2007 Feb 06;2:1
pubmed: 17284314
Neuro Oncol. 2014 Oct;16 Suppl 4:iv1-63
pubmed: 25304271
FEBS Lett. 1998 Sep 25;436(1):6-10
pubmed: 9771884
Molecules. 2017 Jan 19;22(1):
pubmed: 28106855
PLoS One. 2018 Feb 12;13(2):e0192106
pubmed: 29432428
PLoS One. 2009;4(4):e5209
pubmed: 19365568
Bioorg Chem. 2021 Jan;106:104486
pubmed: 33276981
Int J Biochem Cell Biol. 2007;39(4):661-5
pubmed: 17141551
Cancers (Basel). 2010 May 26;2(2):1013-26
pubmed: 24281104
Biomarkers. 2010 Feb;15(1):39-46
pubmed: 19775228
Expert Opin Investig Drugs. 2000 Jul;9(7):1553-71
pubmed: 11060760
J Med Chem. 2007 Oct 18;50(21):5227-37
pubmed: 17900102
Genomics. 2000 Sep 15;68(3):305-12
pubmed: 10995572
Gynecol Oncol. 2017 Dec;147(3):663-671
pubmed: 29079036
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33586682
J Natl Cancer Inst. 1975 Sep;55(3):597-602
pubmed: 1159836
Cell Death Dis. 2021 Apr 7;12(4):377
pubmed: 33828084
Cell Signal. 2005 Jan;17(1):25-37
pubmed: 15451022
Eur J Med Chem. 2019 Oct 15;180:291-309
pubmed: 31319265
FEBS Lett. 1999 Sep 24;458(3):400-4
pubmed: 10570948
Tissue Cell. 2021 Apr;69:101480
pubmed: 33418237
J Biomol Screen. 2013 Mar;18(3):269-76
pubmed: 23015017
J Neurooncol. 2014 Jan;116(1):11-24
pubmed: 24142199
Cancer Cell. 2006 Apr;9(4):301-12
pubmed: 16616335
Int J Mol Sci. 2019 Nov 11;20(22):
pubmed: 31717924
Exp Oncol. 2019 Mar;41(1):7-13
pubmed: 30932401
Curr Oncol. 2016 Mar;23(2):S23-32
pubmed: 27022311
Mol Neurobiol. 2007 Aug;36(1):60-7
pubmed: 17952650
Cancer Res. 2004 Aug 15;64(16):5617-23
pubmed: 15313899
Cancer Res. 2010 Nov 15;70(22):9243-52
pubmed: 20935218
J Natl Cancer Inst. 2013 Oct 2;105(19):1463-73
pubmed: 24052624
Expert Rev Neurother. 2008 Jan;8(1):37-49
pubmed: 18088200
Biomed Pharmacother. 2013 Oct;67(8):693-9
pubmed: 23809372
Pharmaceuticals (Basel). 2019 Mar 26;12(1):
pubmed: 30917521
J Pharmacol Exp Ther. 2004 Mar;308(3):838-45
pubmed: 14617682
Cell Mol Life Sci. 2003 Jun;60(6):1200-8
pubmed: 12861385
Medchemcomm. 2019 Nov 18;10(12):2131-2139
pubmed: 32904145
Mol Cancer. 2013 Apr 25;12:31
pubmed: 23617883
Nat Med. 2000 Mar;6(3):313-9
pubmed: 10700234
Nat Rev Clin Oncol. 2012 May 29;9(7):400-13
pubmed: 22641364
J Med Chem. 2010 Aug 26;53(16):5915-28
pubmed: 20718492
Cancer Res. 2008 Jan 15;68(2):339-42
pubmed: 18199524
Br J Cancer. 2006 Jul 17;95(2):197-203
pubmed: 16804518
Eur J Med Chem. 2015 Jun 5;97:10-8
pubmed: 25935384
Nat Rev Cancer. 2012 May 04;12(6):436-44
pubmed: 22555283
Cancer Sci. 2010 Jan;101(1):173-9
pubmed: 19900191
Neuro Oncol. 2012 Sep;14 Suppl 4:iv90-9
pubmed: 23095836
FASEB J. 2003 Mar;17(3):529-31
pubmed: 12514108
Oncol Rep. 2017 Jan;37(1):465-473
pubmed: 27878289
Nat Rev Cancer. 2003 Oct;3(10):745-55
pubmed: 14570037
ACS Chem Neurosci. 2015 Aug 19;6(8):1445-58
pubmed: 25921407
Int Rev Cell Mol Biol. 2015;314:43-116
pubmed: 25619715
J Med Chem. 2015 Sep 24;58(18):7286-309
pubmed: 26305125
J Transl Med. 2021 Feb 12;19(1):65
pubmed: 33579308
Neuro Oncol. 2019 Aug 5;21(8):968-980
pubmed: 30805642
Tumour Biol. 2017 Jun;39(6):1010428317699131
pubmed: 28618924
PPAR Res. 2017;2017:8187235
pubmed: 28182091
J Pharmacol Sci. 2017 Feb;133(2):96-102
pubmed: 28242177
BMC Clin Pathol. 2012 Feb 28;12:4
pubmed: 22373026
Database (Oxford). 2016 Jul 03;2016:
pubmed: 27374120
Oncol Rep. 2011 Apr;25(4):929-35
pubmed: 21308352
Cancer Chemother Pharmacol. 2009 Mar;63(4):691-701
pubmed: 18629502
Nature. 1980 Aug 14;286(5774):736-7
pubmed: 6997753
Br J Pharmacol. 2005 Apr;144(8):1032-6
pubmed: 15700028
Cancer Res. 2001 Aug 1;61(15):5784-9
pubmed: 11479216
J Med Chem. 2017 Aug 24;60(16):7067-7083
pubmed: 28726401
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Res. 2007 Oct 1;67(19):9528-34
pubmed: 17909063
J Clin Invest. 2019 Mar 1;129(3):1015-1029
pubmed: 30688659
RSC Adv. 2020 Feb 23;10(13):7523-7540
pubmed: 33014349
Cancer Sci. 2016 Oct;107(10):1499-1505
pubmed: 27465934
Cancer Res. 2008 Mar 15;68(6):1945-52
pubmed: 18339876
J Med Chem. 2011 Aug 11;54(15):5444-53
pubmed: 21702498
Biochem J. 2002 Apr 1;363(Pt 1):183-8
pubmed: 11903061
Cell Mol Life Sci. 2006 Sep;63(17):2057-66
pubmed: 16909207